Peptide and oligonucleotide manufacturer Bachem has announced plans to optimise its current production facilities in Bubendorf, Switzerland, St Helens, UK and Vista, California.
The company will also construct a novel peptide manufacturing facility in Sisseln, Switzerland to boost its global manufacturing footprint.
Known as Building K, Bachem's Bubendorf site is responsible for large-scale peptide production, including high-capacity production cells for scalable synthesis, as well as advanced energy systems and a specialised tank farm for large-scale operations.
Through this investment, Bachem will further scale the site's operations, ensuring that the site can meet the growing global demand for therapeutic peptides.
Meanwhile, at its Vista site, Bachem will boost its annual peptide production capacity to nearly one metric tonne.
Following the expansion, the site will house:
- Large-scale SPPS reactors for efficient peptide synthesis
- A cleavage equipment train with two filter dryers
- Increaing tank farm and waste management to support high-volume operations
- Automated glass washer
- New heating/chilling systems for operational efficiency
On top of these expansions, Bachem has doubled the output of its diagnostic peptide manufacturing site in St Helen's, UK.
The company is also developing a new site in Sisseln, Switzerland, with concept designs underway.